Brazilian green propolis hydroalcoholic extract as a therapeutic adjuvant to treat cutaneous leishmaniasis.

Página do item simplificado
dc.contributor.authorCunha, Beatriz Carvalho
dc.contributor.authorMiranda, Marina Barcelos de
dc.contributor.authorAfonso, Luís Carlos Crocco
dc.contributor.authorAbreu, Sheila Rago Lemos
dc.contributor.authorTestasicca, Miriam Conceição de Souza
dc.contributor.authorSilva, Gisele Rodrigues da
dc.contributor.authorMoura, Sandra Aparecida Lima de
dc.date.accessioned2021-11-22T13:45:18Z
dc.date.available2021-11-22T13:45:18Z
dc.date.issued2020pt_BR
dc.description.abstractCutaneous leishmaniasis is caused by Leishmania parasites. There are a limited number of drugs to treat the cutaneous leishmaniasis, and most of them cause severe adverse effects. Therefore, new therapeutic strategies to treat cutaneous leishmaniasis should be developed. In this study, a standardized Brazilian green propolis (BGP) hydroalcoholic extract (Cytopropolis®, Nectar Pharma Brazil) was evaluated as a therapeutic adjuvant, aiming at the treatment of cutaneous leishmaniasis. The antileishmanial effects of different concentrations of BGP hydroalcoholic extract (500, 250, 125, 62.5, 31.25, 15.6, 7.8, and 3.9 µg ml−1) were determined in vitro against amastigotes and promastigotes and in a murine model of leishmaniasis. High concentrations of BGP hydroalcoholic extract (500, 250, 125, and 62.5 µg ml−1) reduced the viability of promastigotes. All concentrations acted against amastigotes. BGP hydroalcoholic extract (500 and 250 µg ml−1) decreased the number of promastigotes in macrophages. In addition, after 2 weeks of oral treatment, BGP hydroalcoholic extract (250 mg/kg/day) decreased the parasites and induced the macrophage infiltration in the lesion caused by the Leishmania amazonensis on the paw of mice. BGP hydroalcoholic extract may represent a therapeutic adjuvant to treat cutaneous leishmaniasis.pt_BR
dc.identifier.citationCUNHA, B. C. et al. Brazilian green propolis hydroalcoholic extract as a therapeutic adjuvant to treat cutaneous leishmaniasis. Journal of Applied Pharmaceutical Science, v. 10, n. 11, p. 124-132, nov. 2020. Disponível em: <https://www.japsonline.com/abstract.php?article_id=3247&sts=2>. Acesso em: 10 jun. 2021.pt_BR
dc.identifier.doihttps://doi.org/10.7324/JAPS.2020.101117pt_BR
dc.identifier.issn2231-3354
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/13995
dc.language.isoen_USpt_BR
dc.rightsabertopt_BR
dc.rights.licenseThis is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). Source: The article PDF.pt_BR
dc.subjectLeishmania amazonensispt_BR
dc.subjectMacrophages.pt_BR
dc.titleBrazilian green propolis hydroalcoholic extract as a therapeutic adjuvant to treat cutaneous leishmaniasis.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Arquivos
Coleções
DECBI - Artigos publicados em periódicos
Carregar mais